23andMe has launched a project funded by the National Institutes of Health (NIH) which is aimed at validating 23andMe's highly-scalable platform for pharmacogenomics research. The company received $190,000 in stimulus funding from the American Recovery and Reinvestment Act of 2009 for "Web-based Phenotyping for Genome-Wide Association Studies of Drug Response" from NIH's National Human Genome Research Institute. "One of 23andMe's research goals is to identify novel pharmacogenetic associations using web-based phenotyping of efficacy and toxicity," said Anne Wojcicki...![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2F-5hsewKwRgx-X4cfajVEToViyME%2F0%2Fdi&hash=418f80078cf2f3945f7f13540f7f16a4)
![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2F-5hsewKwRgx-X4cfajVEToViyME%2F1%2Fdi&hash=3c0fbb44a99ceea21f927f80943ec7bd)
More...
More...